Also written as Aphexda
Motixafortide is a CXCR4 antagonist peptide. It is filed in this library under heart & blood, a navigation topic rather than a statement of where it acts. As a regulatory matter it has at least one product approved by the FDA. It is also written as Aphexda.
Regulatory status
Motixafortide has an FDA-approved product on the U.S. market, marketed as Aphexda under application NDA217159.
The current label is held by Gamida Cell Inc.
From the FDA label
is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.Quoted from the FDA-approved prescribing information
The evidence
One source on Motixafortide, resolved to its journal of record. The title is listed so you can judge the evidence rather than take a summary on trust.
Nearby
A 60-second questionnaire, reviewed by a U.S.-licensed physician.
Find my protocolEducational reference only. This page explains what has been published about Motixafortide. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.
Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.
All 150 peptides